Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  therapeutic autologous lymphocytes
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 80 and under
Trial IDs: MULTIPRAT, NCI-2012-00636, 23637-MULTIPRAT, H-23637, NCT00840853
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
Tumor Infiltrating Lymphocytes after Chemotherapy in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0260, NCI-2013-01506, 110260, P11855, NCT01468818
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-1055, NCI-2014-01040, NCT02027935
CART-19 Cells in Treating Patients With Chemotherapy Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC13413, NCI-2014-00173, 818607, NCT02030834
Laboratory-Treated T-Cells in Treating Patients With Chemotherapy-Resistant or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 21413, NCI-2014-00172, UPCC 21413, NCT02030847
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CCTL019C2201, NCI-2015-01461, 2014-003060-20, NCT02445248
Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: CHARKALL, NCI-2012-00845, H-23574, H-23574-CHARKALL, NCT00881920
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients with Metastatic Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RENAL0027, NCI-2013-01688, NCT01943188
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CM-14-001, NCI-2015-00502, 5R44HL099217-03, NCI-2015-00503, NCT02203825
Start Over